Adicet Bio Inc (ACET) Shares Plummet Below 1-Year High

The stock of Adicet Bio Inc (NASDAQ: ACET) has decreased by -1.67 when compared to last closing price of 2.40. Despite this, the company has experienced a 7.27% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-01 that Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Is It Worth Investing in Adicet Bio Inc (NASDAQ: ACET) Right Now?

Moreover, the 36-month beta value for ACET is 1.86. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for ACET is 67.15M and currently, short sellers hold a 8.66% of that float. On April 03, 2024, ACET’s average trading volume was 1.79M shares.

ACET’s Market Performance

The stock of Adicet Bio Inc (ACET) has seen a 7.27% increase in the past week, with a -1.67% drop in the past month, and a 24.87% gain in the past quarter. The volatility ratio for the week is 5.68%, and the volatility levels for the past 30 days are at 7.13% for ACET. The simple moving average for the past 20 days is 5.10% for ACET’s stock, with a 9.59% simple moving average for the past 200 days.

Analysts’ Opinion of ACET

JP Morgan gave a rating of “Neutral” to ACET, setting the target price at $6 in the report published on June 01st of the previous year.

ACET Trading at -7.78% from the 50-Day Moving Average

After a stumble in the market that brought ACET to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.53% of loss for the given period.

Volatility was left at 7.13%, however, over the last 30 days, the volatility rate increased by 5.68%, as shares sank -0.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.28% lower at present.

During the last 5 trading sessions, ACET rose by +7.27%, which changed the moving average for the period of 200-days by -47.90% in comparison to the 20-day moving average, which settled at $2.24. In addition, Adicet Bio Inc saw 24.87% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ACET starting from ORBIMED ADVISORS LLC, who purchase 3,125,000 shares at the price of $2.40 back on Jan 25 ’24. After this action, ORBIMED ADVISORS LLC now owns 7,526,359 shares of Adicet Bio Inc, valued at $7,500,000 using the latest closing price.

GORDON CARL L, the Director of Adicet Bio Inc, purchase 3,125,000 shares at $2.40 during a trade that took place back on Jan 25 ’24, which means that GORDON CARL L is holding 7,526,359 shares at $7,500,000 based on the most recent closing price.

Stock Fundamentals for ACET

The total capital return value is set at -0.81. Equity return is now at value -61.69, with -53.03 for asset returns.

Based on Adicet Bio Inc (ACET), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -4.48. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -6335.0.

Currently, EBITDA for the company is -126.48 million with net debt to EBITDA at 1.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.41.

Conclusion

To wrap up, the performance of Adicet Bio Inc (ACET) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts